BACKGROUND	In two studies it has been shown to halve the rates of depression recurring compared to usual care.This trial asks the policy research question , is MBCT superior to m-ADM in terms of : a primary outcome of preventing depressive relapse/recurrence over 24 months ; and , secondary outcomes of ( a ) depression free days , ( b ) residual depressive symptoms , ( c ) antidepressant ( ADM ) usage , ( d ) psychiatric and medical co-morbidity , ( e ) quality of life , and ( f ) cost effectiveness ?\